Ikena Oncology Inc (NAS:IKNA)
$ 1.735 -0.115 (-6.22%) Market Cap: 83.73 Mil Enterprise Value: -47.05 Mil PE Ratio: 0 PB Ratio: 0.59 GF Score: 30/100

Ikena Oncology Inc at Stifel Healthcare Conference (Virtual) Transcript

Nov 15, 2021 / 04:20PM GMT
Release Date Price: $16.2 (-4.48%)
Stephen Douglas Willey
Stifel, Nicolaus & Company, Incorporated, Research Division - Director

All right. Good morning. I'm Stephen Willey, one of the senior biotech analysts here at Stifel and glad to have with us this morning presenting Ikena Oncology. We have Mark Manfredi, who is the CEO; we have Doug Carlson, who is the CFO; and we have Sergio Santillana, who is the Chief Medical Officer. Mark is going to walk us through a presentation, give us an overview of the company. We should have some time at the end for Q&A.

I'm going to hand it over to Mark, and thanks for being here this morning, Mark.

Mark Manfredi
Ikena Oncology, Inc. - President. CEO & Director

Thanks, Stephen. Thanks for the invitation to present Ikena. So I'll be making some forward-looking statements.

So we are an oncology company, clinical stage and focused in targeted agents in two areas. One is the immune signaling in the tumor microenvironment, where we're working in programs in the immunometabolism, and we'll talk about one of those programs today. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot